Avacta Group PLC (AVCT)

London
126.40
+14.00(+12.61%)
  • Volume:
    2,663,432
  • Bid/Ask:
    123.00/128.00
  • Day's Range:
    118.40 - 126.40

AVCT Overview

Prev. Close
111
Day's Range
118.4-126.4
Revenue
5.26M
Open
110.5
52 wk Range
38-262
EPS
-0.11
Volume
2,663,432
Market Cap
321.99M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
2,073,828
P/E Ratio
-
Beta
2.04
1-Year Change
-56.16%
Shares Outstanding
253,933,912
Next Earnings Date
27 Sept 2022
What is your sentiment on Avacta Group?
or
Market is currently closed. Voting is open during market hours.

Avacta Group PLC News

Avacta Group PLC Analysis

Avacta Group PLC Company Profile

Avacta Group PLC Company Profile

Employees
123

Avacta Group plc is a United Kingdom-based clinical stage biopharmaceutical company. The Company is focused on developing cancer therapies and diagnostics based on its Affimer and prelCISION platforms. The Company operates through three segments: Diagnostics, Therapeutics and Animal Health. Its Diagnostics segment is engaged in the development of custom Affimer proteins for incorporation into customer products and in-house diagnostic assays. Its Therapeutics segment is engaged in the development of cancer immunotherapies combining its platforms. Its Animal Health segment is engaged in the provision of tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians. The Company's diagnostics division is focused on utilizing its Affimer platform to develop AffiDX in vitro diagnostic (IVD) tests, which include AffiDX SARS-CoV-2 Antigen Lateral Flow Test.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellBuyBuyStrong BuyBuy
Technical IndicatorsBuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryNeutralStrong BuyStrong BuyStrong BuyNeutral
  • Its all about the AVA
    0
    • Anyone else just think Avacta have had 2 years to get a test out yet how did all the Chinese tests got there a year and a half earlier?
      3
      • and how are the Chinese test kits testing for the new variants that keep coming?
        0
      • Its called “corruption”.
        0
    • Or even ********
      3
      • ETF!
        1
        • UK demand alone for 'accurate' & easy to perform rapid lateral flow tests is apparently running at c. 1.8m units/day. Thus hypothetically at say £5 each, that's a revenue run-rate (whilst schools are open) of £9m/day, or >£200m/month. Not bad news for the likes of Avacta, Omega Diagnostics & Abingdon health, along with PCR testing firms such as Novacyt & SourceBio Internationa, who should also benefit from extra 'knock-on' confirmatory volume having to be performed by their mobile/fixed labs.
          2
          • All coming speedily to fruition, with regard to the covid test’s. The cash gsnerated will fund th Ed cancer side. This will bs the major bread winner. Of course after a future Nasdaq quoute, this will most likely lead to a take out by sons big pharma. Buy now, in the next 3 weeks this share will be much higher, imo
            0
            • why such a bounce? now back to where it was 2 days ago
              0
              • FOMO Friday
                0
            • am l the only one thinks once the manufacturing details are released this will go to at least £4? With the LFT printing money every second for the next year at least, a buyback, special dividend or takeover has to be on the cards, likely the later given the start of that ava6000 cancer therapy trials.
              2
              • buy and hold...as the new spread re the tests it should boost price further.
                1
              • This will be sales of LFT test kits in the UK, then Europe and even world wide could follow, so it could go much higher, 👍
                0
            • Avacta have the best rapid antigen test going. Only one way from here...
              3
              • SP finally going down. CEO has a nice house from the sale proceeds
                5
                • CEO sold some of his holding. So? Guess he could have sold out completely if he had no faith.
                  1